A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteer (Q34298776)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteer |
scientific article |
Statements
1 reference
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteer (English)
1 reference
F Joel Leong
1 reference
Ruobing Li
1 reference
Jay Prakash Jain
1 reference
Gilbert Lefèvre
1 reference
Baldur Magnusson
1 reference
Thierry T Diagana
1 reference
Peter Pertel
1 reference
11 August 2014
1 reference
1 reference
Identifiers
1 reference